The field of cardio-oncology and the potential for subsequent cardiotoxicity in patients receiving cancer care – becoming symptomatic perhaps as late as five to ten years post-treatment – have become better known by clinicians in recent years. Researchers in Spain crystallized the link some 13 years ago.
More recently, guidelines issued by the European Society of Cardiology (ESC) and Canada, and a greater research focus on the...